Profiling of autoantibodies in the sera of glioblastoma patients

Immunotherapy. 2024;16(16-17):1049-1056. doi: 10.1080/1750743X.2024.2390350. Epub 2024 Sep 12.

Abstract

Aim: This study aimed to determine the expression pattern of autoantibody proteins from the serum of grade IV glioblastoma patients.Materials & methods: We performed high throughput antibody profiling via the Sengenics i-Ome® Protein Array to determine the differentially expressed autoantibodies.Results: The results portrayed that anti-COL4A3BP and anti-HSP90AA1 were among the upregulated autoantibodies in glioblastoma sera.Conclusion: The selected autoantibodies offer promising targets for future glioblastoma pathogenesis. However, further validation is required to elucidate the autoantibody signature in glioblastoma patients.

Keywords: KREX; autoantibodies; glioblastoma; liquid biopsy; microarray.

Plain language summary

Glioblastoma is a disease affecting many people. Herein we have identified several proteins called autoantibodies that are abundant in the serum of glioblastoma patients and can be used as targets to treat or diagnose this disease.

MeSH terms

  • Adult
  • Aged
  • Autoantibodies* / blood
  • Autoantibodies* / immunology
  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / immunology
  • Brain Neoplasms / blood
  • Brain Neoplasms / immunology
  • Female
  • Glioblastoma* / blood
  • Glioblastoma* / immunology
  • HSP90 Heat-Shock Proteins / immunology
  • Humans
  • Male
  • Middle Aged

Substances

  • Autoantibodies
  • HSP90 Heat-Shock Proteins
  • Biomarkers, Tumor